On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns ...

Eli Lilly (NYSE:LLY) shares reached a new 52-week low on Thursday as concerns over late-stage trial data for the company’s highly anticipated oral weight loss therapy, orforglipron, overshadowed its ...

The second phase is likely to match or exceed Phase 1's scale, with possible additions like agrovoltaics and minor guideline revisions ...

As crypto markets stir with anticipation for the next bull cycle, Mutuum Finance (MUTM) and Solana (SOL) are the names ...

NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque ...

Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...

GAAP revenue of $14.2 million for Q2 2025 beat analyst estimates and Revenue more than doubled year over year in the second quarter, beating analyst estimates. Net loss per share (GAAP) narrowed to ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight ...

The OBBBA is long an complicated, here are 7 strategies for high-income California business owner to minimize their tax this ...

A machine learning method developed by researchers from the Institute of Science Tokyo, the Institute of Statistical ...

FC Cincinnati closes Phase One of Leagues Cup play Thursday night against Chivas Guadalajara. Here's what needs to happen for ...

It looks likely we'll see oral GLP-1 drugs on the market by next year, with pharmaceutical company Eli Lilly reporting ...